RT Journal Article
SR Electronic
T1 25-Year Follow-up of HIV-positive Patients with Benign Lymphoepithelial Cysts of the Parotid Glands: A Retrospective Review
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 4927
OP 4932
VO 33
IS 11
A1 WALEED F. MOURAD
A1 REBEKAH YOUNG
A1 RAFI KABARRITI
A1 DUKAGJIN M. BLAKAJ
A1 RANIA A. SHOURBAJI
A1 JONATHAN GLANZMAN
A1 SHYAMAL PATEL
A1 NITIN OHRI
A1 RAVINDRA YAPARPALVI
A1 JONATHAN J. BEITLER
A1 SHALOM KALNICKI
A1 MADHUR K. GARG
YR 2013
UL http://ar.iiarjournals.org/content/33/11/4927.abstract
AB Aim: To report long-term outcomes for HIV-positive patients who underwent radiation therapy (RT) for benign lymphoepithelial cysts (BLEC) of the parotid glands. Patients and Methods: In this single institution retrospective study of HIV-associated BLEC of the parotids, the medical records of 37 HIV-positive patients who were treated with RT between 1987-2012 were reviewed. Patients were stratified into two groups; group A consisted of 15 patients (40.5%) who received a total dose of ≤18Gy, with a median dose 10 Gy (range 8-18Gy), and group B consisted of 22 patients (59.5%) who received a total dose of 24 Gy. In addition to dosing information, additional patient data were collected, including demographics, HAART compliance, follow-up, and re-treatment status. Results: The median age at the time of treatment was 41 (range=7-70) years. With a median follow-up of 35 (range=12-75) months for the entire cohort, the complete response (CR) and partial response (PR) rates were 35% and 8%, respectively. All but one of 15 patients in Group A (lower total dose) eventually experienced local failure with the re-emergence of parotid hypertrophy. Among the patients in group B (higher total dose of 24 Gy), 55%, 13%, and 32% experienced CR, PR, and LF, respectively. Median times to failure in groups A and B were 7 and 20 months, respectively (p<0.0001). Similarly, logistic regression test revealed the higher dose to be associated with better response rate (i.e. CR or PR) (p<0.0001), which was also statistically significant (p=0.03) after adjusting for confounding variables (age, race, gender, HAART use, and fractionation). Conclusion: A total dose of 24 Gy continues to be recommended for durable cosmetic control of BLEC of the parotid glands that is associated with HIV-seropositivity.